Details for New Drug Application (NDA): 214921
✉ Email this page to a colleague
NDA 214921 describes BRIVARACETAM, which is a drug marketed by Aurobindo Pharma Ltd, Lupin Ltd, MSN, Sunshine, and Zydus Pharms, and is included in five NDAs. It is available from five suppliers. Additional details are available on the BRIVARACETAM profile page.
The generic ingredient in BRIVARACETAM is brivaracetam. Six suppliers are listed for this compound. Additional details are available on the brivaracetam profile page.
The generic ingredient in BRIVARACETAM is brivaracetam. Six suppliers are listed for this compound. Additional details are available on the brivaracetam profile page.
Summary for 214921
| Tradename: | BRIVARACETAM |
| Applicant: | Msn |
| Ingredient: | brivaracetam |
| Patents: | 0 |
Pharmacology for NDA: 214921
| Mechanism of Action | Epoxide Hydrolase Inhibitors |
Suppliers and Packaging for NDA: 214921
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BRIVARACETAM | brivaracetam | TABLET;ORAL | 214921 | ANDA | Novadoz Pharmaceuticals LLC | 72205-267 | 72205-267-60 | 60 TABLET, FILM COATED in 1 BOTTLE (72205-267-60) |
| BRIVARACETAM | brivaracetam | TABLET;ORAL | 214921 | ANDA | Novadoz Pharmaceuticals LLC | 72205-268 | 72205-268-06 | 100 BLISTER PACK in 1 CARTON (72205-268-06) / 1 TABLET, FILM COATED in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Nov 13, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Nov 13, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Nov 13, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
